ES2582605T3 - Decorina para su uso en el tratamiento de afecciones neurológicas traumáticas por administración por vía intratecal - Google Patents
Decorina para su uso en el tratamiento de afecciones neurológicas traumáticas por administración por vía intratecal Download PDFInfo
- Publication number
- ES2582605T3 ES2582605T3 ES11852038.6T ES11852038T ES2582605T3 ES 2582605 T3 ES2582605 T3 ES 2582605T3 ES 11852038 T ES11852038 T ES 11852038T ES 2582605 T3 ES2582605 T3 ES 2582605T3
- Authority
- ES
- Spain
- Prior art keywords
- decorin
- functional fragment
- spinal cord
- injury
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004237 Decorin Human genes 0.000 title claims abstract description 134
- 108090000738 Decorin Proteins 0.000 title claims abstract description 131
- 230000000926 neurological effect Effects 0.000 title claims abstract description 62
- 238000007913 intrathecal administration Methods 0.000 title claims abstract description 49
- 230000000472 traumatic effect Effects 0.000 title claims abstract description 38
- 238000011282 treatment Methods 0.000 title claims description 49
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 71
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000012634 fragment Substances 0.000 claims abstract 29
- 208000014674 injury Diseases 0.000 claims description 89
- 230000006378 damage Effects 0.000 claims description 86
- 208000027418 Wounds and injury Diseases 0.000 claims description 83
- 210000000278 spinal cord Anatomy 0.000 claims description 77
- 238000011084 recovery Methods 0.000 claims description 57
- 210000003050 axon Anatomy 0.000 claims description 48
- 230000028600 axonogenesis Effects 0.000 claims description 47
- 238000001802 infusion Methods 0.000 claims description 38
- 210000001519 tissue Anatomy 0.000 claims description 36
- 231100000241 scar Toxicity 0.000 claims description 26
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 claims description 25
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 claims description 25
- 210000004884 grey matter Anatomy 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 230000001629 suppression Effects 0.000 claims description 22
- 230000001537 neural effect Effects 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 20
- 238000002560 therapeutic procedure Methods 0.000 claims description 19
- 239000003112 inhibitor Substances 0.000 claims description 17
- 230000006870 function Effects 0.000 claims description 16
- 108010088842 Fibrinolysin Proteins 0.000 claims description 14
- 239000003966 growth inhibitor Substances 0.000 claims description 14
- 210000002569 neuron Anatomy 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 108010083674 Myelin Proteins Proteins 0.000 claims description 12
- 102000006386 Myelin Proteins Human genes 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 210000005012 myelin Anatomy 0.000 claims description 12
- 229940012957 plasmin Drugs 0.000 claims description 12
- 230000036573 scar formation Effects 0.000 claims description 12
- 230000007658 neurological function Effects 0.000 claims description 10
- 230000003827 upregulation Effects 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- 102000013566 Plasminogen Human genes 0.000 claims description 7
- 108010051456 Plasminogen Proteins 0.000 claims description 7
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 7
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 7
- 239000003638 chemical reducing agent Substances 0.000 claims description 7
- 206010018341 Gliosis Diseases 0.000 claims description 6
- 208000037875 astrocytosis Diseases 0.000 claims description 6
- 230000007341 astrogliosis Effects 0.000 claims description 6
- 230000003176 fibrotic effect Effects 0.000 claims description 6
- 102000045840 human DCN Human genes 0.000 claims description 6
- 239000002105 nanoparticle Substances 0.000 claims description 5
- 210000000115 thoracic cavity Anatomy 0.000 claims description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 239000012620 biological material Substances 0.000 claims description 4
- 210000003164 cauda equina Anatomy 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 101001000206 Homo sapiens Decorin Proteins 0.000 claims description 3
- 206010021143 Hypoxia Diseases 0.000 claims description 3
- 206010070834 Sensitisation Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 230000001594 aberrant effect Effects 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 230000002631 hypothermal effect Effects 0.000 claims description 3
- 230000001146 hypoxic effect Effects 0.000 claims description 3
- 239000007943 implant Substances 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 230000008313 sensitization Effects 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 238000011477 surgical intervention Methods 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 241000237536 Mytilus edulis Species 0.000 claims description 2
- 238000009207 exercise therapy Methods 0.000 claims description 2
- 235000020638 mussel Nutrition 0.000 claims description 2
- 210000001787 dendrite Anatomy 0.000 claims 1
- 102000001732 Small Leucine-Rich Proteoglycans Human genes 0.000 description 79
- 108010040068 Small Leucine-Rich Proteoglycans Proteins 0.000 description 79
- 241000700159 Rattus Species 0.000 description 78
- 208000020431 spinal cord injury Diseases 0.000 description 62
- 210000003414 extremity Anatomy 0.000 description 40
- 230000014509 gene expression Effects 0.000 description 29
- 238000004458 analytical method Methods 0.000 description 25
- 210000004556 brain Anatomy 0.000 description 25
- 210000000078 claw Anatomy 0.000 description 25
- 230000003902 lesion Effects 0.000 description 25
- 230000008929 regeneration Effects 0.000 description 21
- 238000011069 regeneration method Methods 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 20
- 208000034656 Contusions Diseases 0.000 description 19
- 230000009519 contusion Effects 0.000 description 19
- 230000001154 acute effect Effects 0.000 description 16
- 210000003141 lower extremity Anatomy 0.000 description 14
- 108010025020 Nerve Growth Factor Proteins 0.000 description 13
- 102000017299 Synapsin-1 Human genes 0.000 description 13
- 108050005241 Synapsin-1 Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000003137 locomotive effect Effects 0.000 description 11
- 238000002203 pretreatment Methods 0.000 description 11
- 108010043296 Neurocan Proteins 0.000 description 10
- 102100030466 Neurocan core protein Human genes 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 10
- 108010085074 Brevican Proteins 0.000 description 9
- 102100032312 Brevican core protein Human genes 0.000 description 9
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 9
- 102000006452 Class 5 Receptor-Like Protein Tyrosine Phosphatases Human genes 0.000 description 9
- 108010044213 Class 5 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 description 9
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 9
- 101001107084 Homo sapiens E3 ubiquitin-protein ligase RNF5 Proteins 0.000 description 9
- 102000007072 Nerve Growth Factors Human genes 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 230000005021 gait Effects 0.000 description 9
- 239000003102 growth factor Substances 0.000 description 9
- 210000004885 white matter Anatomy 0.000 description 9
- 239000011521 glass Substances 0.000 description 8
- 210000000225 synapse Anatomy 0.000 description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- 210000001130 astrocyte Anatomy 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 210000002744 extracellular matrix Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000003447 ipsilateral effect Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- -1 versica n V2 Proteins 0.000 description 7
- 102000016611 Proteoglycans Human genes 0.000 description 6
- 108010067787 Proteoglycans Proteins 0.000 description 6
- 102100027974 Semaphorin-3A Human genes 0.000 description 6
- 108010090319 Semaphorin-3A Proteins 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 229920001287 Chondroitin sulfate Polymers 0.000 description 5
- 102000014105 Semaphorin Human genes 0.000 description 5
- 108050003978 Semaphorin Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000004901 leucine-rich repeat Anatomy 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000000274 microglia Anatomy 0.000 description 5
- 210000002161 motor neuron Anatomy 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000008736 traumatic injury Effects 0.000 description 5
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 description 4
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 4
- 102000001435 Synapsin Human genes 0.000 description 4
- 108050009621 Synapsin Proteins 0.000 description 4
- 210000004960 anterior grey column Anatomy 0.000 description 4
- 230000003376 axonal effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000003609 chemorepellent Effects 0.000 description 4
- 239000002838 chemorepellent Substances 0.000 description 4
- 229940059329 chondroitin sulfate Drugs 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 210000002418 meninge Anatomy 0.000 description 4
- 229940053128 nerve growth factor Drugs 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 230000006320 pegylation Effects 0.000 description 4
- 210000001428 peripheral nervous system Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 230000003956 synaptic plasticity Effects 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 108010008125 Tenascin Proteins 0.000 description 3
- 102000007000 Tenascin Human genes 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000002424 anti-apoptotic effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000000576 arachnoid Anatomy 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 3
- 210000005056 cell body Anatomy 0.000 description 3
- 210000004720 cerebrum Anatomy 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 230000002518 glial effect Effects 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000000508 neurotrophic effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 210000002804 pyramidal tract Anatomy 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 210000003625 skull Anatomy 0.000 description 3
- 210000001032 spinal nerve Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000002504 synaptic vesicle Anatomy 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 240000008213 Brosimum alicastrum Species 0.000 description 2
- 229920002567 Chondroitin Polymers 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 229920000045 Dermatan sulfate Polymers 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 108010077641 Nogo Proteins Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 208000020339 Spinal injury Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000003510 anti-fibrotic effect Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000009689 neuronal regeneration Effects 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 235000005828 ramon Nutrition 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000273 spinal nerve root Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102000004954 Biglycan Human genes 0.000 description 1
- 108090001138 Biglycan Proteins 0.000 description 1
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 1
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000001308 Fasciculation Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000017177 Fibromodulin Human genes 0.000 description 1
- 108010013996 Fibromodulin Proteins 0.000 description 1
- 241000948258 Gila Species 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000611663 Homo sapiens Prolargin Proteins 0.000 description 1
- 206010022528 Interactions Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011681 Lumican Human genes 0.000 description 1
- 108010076371 Lumican Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 101100027996 Mus musculus Omg gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028293 Muscle contractions involuntary Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 102100031688 N-acetylgalactosamine-6-sulfatase Human genes 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102100028762 Neuropilin-1 Human genes 0.000 description 1
- 108090000772 Neuropilin-1 Proteins 0.000 description 1
- 102000010410 Nogo Proteins Human genes 0.000 description 1
- CIQHWLTYGMYQQR-QMMMGPOBSA-N O(4')-sulfo-L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OS(O)(=O)=O)C=C1 CIQHWLTYGMYQQR-QMMMGPOBSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100040659 Prolargin Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100029831 Reticulon-4 Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108090001076 Synaptophysin Proteins 0.000 description 1
- 102000004874 Synaptophysin Human genes 0.000 description 1
- 101150109894 TGFA gene Proteins 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003198 cerebellar cortex Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002594 corticospinal effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 108010041738 decorin receptor Proteins 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000003479 dental cement Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 230000003503 early effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000002449 erythroblastic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 210000000020 growth cone Anatomy 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000000343 hippocampal mossy fiber Anatomy 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000028756 lack of coordination Diseases 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 230000007775 late Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000007996 neuronal plasticity Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 210000000103 occipital bone Anatomy 0.000 description 1
- 101150111393 oli gene Proteins 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 210000003446 pia mater Anatomy 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 208000035736 spondylodysplastic type Ehlers-Danlos syndrome Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000027912 synapse maturation Effects 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 201000006361 tethered spinal cord syndrome Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 238000010153 Šidák test Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061424769P | 2010-12-20 | 2010-12-20 | |
| US201061424769P | 2010-12-20 | ||
| PCT/US2011/066199 WO2012088133A1 (en) | 2010-12-20 | 2011-12-20 | Methods for treating neurological conditions and compositions and materials therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2582605T3 true ES2582605T3 (es) | 2016-09-14 |
Family
ID=46235329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11852038.6T Active ES2582605T3 (es) | 2010-12-20 | 2011-12-20 | Decorina para su uso en el tratamiento de afecciones neurológicas traumáticas por administración por vía intratecal |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9061047B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2654899B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5883027B2 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2011349256B2 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2582605T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2012088133A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011349256B2 (en) | 2010-12-20 | 2017-01-05 | Scidec Therapeutics, Inc. | Methods for treating neurological conditions and compositions and materials therefor |
| WO2015089443A2 (en) * | 2013-12-12 | 2015-06-18 | The Brigham And Women's Hospital, Inc. | Treating neurodegenerative disease |
| CN104173938B (zh) * | 2014-08-29 | 2017-03-01 | 李从达 | 一种治疗脊髓栓系综合征的中药制剂 |
| GB202314158D0 (en) * | 2023-09-15 | 2023-11-01 | Senorei Ltd | Inhibition of vascular leakage |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612038B2 (en) | 1999-11-18 | 2009-11-03 | Brown University | Biglycan and related therapeutics and methods of use |
| US8419710B2 (en) | 2006-12-06 | 2013-04-16 | Medtronic, Inc. | Methods for infusing fluids via an implantable infusion system |
| JP2010047533A (ja) * | 2008-08-22 | 2010-03-04 | Mitsubishi Gas Chemical Co Inc | 脊髄損傷改善剤 |
| WO2010065917A1 (en) * | 2008-12-05 | 2010-06-10 | The Regents Of The University Of California | Methods of treating neurological disorders |
| AU2011349256B2 (en) * | 2010-12-20 | 2017-01-05 | Scidec Therapeutics, Inc. | Methods for treating neurological conditions and compositions and materials therefor |
-
2011
- 2011-12-20 AU AU2011349256A patent/AU2011349256B2/en active Active
- 2011-12-20 ES ES11852038.6T patent/ES2582605T3/es active Active
- 2011-12-20 JP JP2013546331A patent/JP5883027B2/ja active Active
- 2011-12-20 EP EP11852038.6A patent/EP2654899B1/en active Active
- 2011-12-20 US US13/331,933 patent/US9061047B2/en active Active
- 2011-12-20 WO PCT/US2011/066199 patent/WO2012088133A1/en not_active Ceased
-
2015
- 2015-05-18 US US14/714,626 patent/US9592276B2/en active Active
-
2017
- 2017-01-30 US US15/419,116 patent/US10258670B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2654899A4 (en) | 2014-08-20 |
| EP2654899A1 (en) | 2013-10-30 |
| US20170136098A1 (en) | 2017-05-18 |
| EP2654899B1 (en) | 2016-05-25 |
| JP2014500327A (ja) | 2014-01-09 |
| US20150250859A1 (en) | 2015-09-10 |
| US20120157976A1 (en) | 2012-06-21 |
| US9061047B2 (en) | 2015-06-23 |
| US9592276B2 (en) | 2017-03-14 |
| US10258670B2 (en) | 2019-04-16 |
| AU2011349256B2 (en) | 2017-01-05 |
| WO2012088133A1 (en) | 2012-06-28 |
| HK1190652A1 (zh) | 2014-07-11 |
| JP5883027B2 (ja) | 2016-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brodkey et al. | The complex nature of interactive neuroregeneration-related molecules | |
| JP5607176B2 (ja) | 新規ペプチドおよびその用途 | |
| Shields et al. | Benefit of chondroitinase ABC on sensory axon regeneration in a laceration model of spinal cord injury in the rat | |
| Anderberg et al. | Spinal cord injury–scientific challenges for the unknown future | |
| CA3233345A1 (en) | Compositions and methods for inhibiting the activity of lar family phosphatases | |
| ES2420510T3 (es) | Composiciones y métodos para el tratamiento de lesiones del SNC | |
| EP1993589A2 (en) | Treatments for neurological disorders | |
| US10258670B2 (en) | Methods for treating neurological conditions and compositions and materials therefor | |
| AU2011349256A1 (en) | Methods for treating neurological conditions and compositions and materials therefor | |
| US20180042984A1 (en) | Pharmaceutical composition for preventing or treating arthritis | |
| TWI913886B (zh) | Cxcl14為基礎之促進軟骨再生的組合物及方法 | |
| CN118001373B (zh) | 一种治疗骨关节炎的药物 | |
| CN112969706A (zh) | 刺激细胞外基质合成的葡糖胺的氨基酸衍生物和包含其的药物组合物 | |
| US20180066027A1 (en) | Protamine in treatment of neuronal injuries | |
| WO2023034993A1 (en) | Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases | |
| HK1190652B (en) | Decorin for use in treating traumatic neurological conditions via intrathecal administration | |
| Milton | Chronic Systemic Manipulation of Axonal Inhibitory Perineuronal Net and rPTPσ Promotes Forelimb Recovery and Neuroplasticity | |
| Shanmugalingam | Exploring novel molecular approaches to promote repair of the damaged nervous system: A role for Neuronal Pentraxin 2 | |
| US9095551B2 (en) | Combined preparation for treating joint diseases | |
| Gunay et al. | The effectiveness of tetanus toxin on sciatic nerve regeneration: a preliminary experimental study in rats | |
| Urban | Targeted Restoration of Respiratory Neural Circuitry following Cervical Spinal Cord Injury | |
| Hossain-Ibrahim | Studies on axonal regeneration in the CNS and peripheral nerves | |
| CN120392996A (zh) | Cd22抗体在制备治疗脊髓损伤相关疾病的药物中的应用 | |
| WO2020223299A1 (en) | Methods and compositions for treating cns injury | |
| Irvine | Perineuronal nets in recovery after acute spinal cord injury |